This article is more than 5 years old. Information may no longer be current.
Vitrisa Therapeutics acquires select rights to MAKO clinical trial database
Click Here to Manage Email Alerts
Vitrisa Therapeutics has entered into an option agreement with Ohr Pharmaceutical for certain rights to the data from the MAKO study in wet age-related macular degeneration.
Under the agreement, Vitrisa will receive initial nonexclusive rights to the data and a time-limited option to acquire worldwide exclusive ownership of the trial database. Vitrisa plans to use the data set to run virtual clinical trials and evaluate clinical strategies for wet AMD, according to a company press release.
The MAKO study was a 237-patient clinical trial to evaluate the efficacy and safety of squalamine and Lucentis (ranibizumab, Genentech) combination therapy vs. ranibizumab monotherapy for wet AMD. Ohr previously reported that the primary endpoint of the study was not met.
Vitrisa, through an upfront payment, will gain initial nonexclusive access to summary data for the ranibizumab monotherapy arm. The company will have the option to acquire worldwide exclusive ownership of the entire database for 90 days after the initial access.